Abstract
The value of the HER2DX genomic assay in patients with advanced HER2+ disease is currently unknown. Here, we evaluated the association of the information provided by the HER2DX assay with T-DM1 benefit and survival.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
